Skip to content
OpenCapital
Get started

United Therapeutics UTHR Q1 2025 earnings

Reported April 30, 2025 · Before market open

Revenue$794.4MBeat by $15.7MDiluted EPS$6.63Beat by $0.34
Revenue estimate$778.7M
EPS estimate$6.29

Next report

Jul 29, 2026 (In 4 days)
Revenue estimate$805.0M
EPS estimate$7.06

Financials

Q1 2025

Income statement

See full
Revenue$794.4M+17.2%
Gross profit$701.9M+16.1%
Operating income$382.8M+7.4%
Net income$322.2M+5.1%
EPS (diluted)$6.63+7.5%

Balance sheet

See full
Cash & equivalents$1.9B+51.8%
Total equity$6.8B+27.5%
Total assets$7.7B+19.2%

Cash flow

See full
Operating cash flow$461.2M+22.5%
CapEx$74.9M+96.1%
Free cash flow$386.3M+14.2%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$13.85B+28.2%
P/E11.4×+1.2×
P/S4.6×+0.3×

Profitability

See full
Gross margin89%+0.1pp
Operating margin46.9%-3.4pp
Net margin40.4%-1.6pp
FCF margin37.7%+7.6pp

Returns & leverage

See full
Return on equity19.9%-0.1pp
Current ratio5.5×+1.7×

Segments

By product

See full
Tyvaso DPI$302.5M+33.0%
Nebulized Tyvaso$163.8M+13.0%
Remodulin$138.2M+8.0%
Orenitram$120.7M+13.7%
Unituxin$58.2M-0.3%

By geography

See full
U.S.$749.6M—

Versus estimates

Revenue

Q1 2026$781.5MMiss by $15.9MQ4 2025$790.2MMiss by $22.9MQ3 2025$799.5MMiss by $15.3MQ2 2025$798.6MMiss by $3.3M
Q1 2025$794.4MBeat by $15.7M
Q4 2024$735.9MBeat by $1.2M

Diluted EPS

Q1 2026$5.82Miss by $1.18Q4 2025$7.70Beat by $0.57Q3 2025$7.16Beat by $0.27Q2 2025$6.41Miss by $0.88
Q1 2025$6.63Beat by $0.34
Q4 2024$6.19Miss by $0.21

Ask the moment United Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did United Therapeutics report Q1 2025 earnings?
United Therapeutics (UTHR) reported Q1 2025 earnings on April 30, 2025 before market open.
What were United Therapeutics's Q1 2025 revenue and EPS?
United Therapeutics reported revenue of $794.4M and diluted EPS of $6.63 for Q1 2025.
Did United Therapeutics beat estimates in Q1 2025?
Revenue beat the consensus estimate of $778.7M by $15.7M. EPS beat the consensus estimate of $6.29 by $0.34.
How did United Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 17.2% from $677.7M a year earlier and diluted EPS grew 7.5% from $6.17.
Where can I find United Therapeutics's Q1 2025 SEC filings?
You can read the 10-Q periodic report (0001082554-25-000023) directly on SEC EDGAR. The filing index links above go to sec.gov.